~ Breakthrough Therapy designation based on clinical evidence from Phase I/II trials showing meaningful slowing of disease progression ~ ~ Additional regulatory update and guidance on the Biologics License Application
Roche has announced the continuation of the GENERATION HD2 Phase II clinical trial evaluating tominersen in individuals with early signs of Huntington’s disease. Following an interim analysis by an independent committee, no
Living with Huntington’s Disease (HD) often feels like a series of quiet, and sometimes loud goodbyes. We say goodbye to the way our bodies used to move, to the stamina
The HDYO Congress 2025 brought together young people, families, researchers, and professionals from around the world for an unforgettable event dedicated to the Huntington’s Disease community. Over three inspiring days,
“Gratitude Day is a way to honor the collaboration of HD families with clinicians and scientists, which started with the efforts to identify the Huntington’s disease gene in the 1980s,
Tanita Allen, a dedicated advocate for Huntington’s Disease and author of her much labored memoir “We Exist”, is starting a new column for the IHA website, called Be Empowered by
La conferința EHDN & Enroll-HD de anul trecut de la Strasbourg, am avut privilegiul de a o intervieva pe Siri Hagen Kjølaas, Ph.D., pentru a discuta despre cercetarea sa inovatoare privind provocările psihosociale cu care se confruntă
SOM Biotech prezintă rezultatele studiului de fază 2b cu SOM3355, demonstrând un profil unic cu îmbunătățiri robuste ale coreei la pacienții cu boala Huntington și un profil sigur fără somnolență,
Asociația Internațională Huntington, în colaborare cu Asociația Europeană Huntington, organizează o campanie pentru Ziua Bolilor Rare 2025, pe 28 februarie. Sloganul pentru RDD din acest an
Rare Diseases International (RDI) a anunțat lansarea RDI Youth Leadership Programme, o inițiativă menită să implice și să responsabilizeze tinerii din cadrul comunității bolilor rare. Acest program urmărește
~ Breakthrough Therapy designation based on clinical evidence from Phase I/II trials showing meaningful slowing of disease progression ~ ~ Additional regulatory update and guidance on the Biologics License Application
Roche has announced the continuation of the GENERATION HD2 Phase II clinical trial evaluating tominersen in individuals with early signs of Huntington’s disease. Following an interim analysis by an independent committee, no
Living with Huntington’s Disease (HD) often feels like a series of quiet, and sometimes loud goodbyes. We say goodbye to the way our bodies used to move, to the stamina
The HDYO Congress 2025 brought together young people, families, researchers, and professionals from around the world for an unforgettable event dedicated to the Huntington’s Disease community. Over three inspiring days,
“Gratitude Day is a way to honor the collaboration of HD families with clinicians and scientists, which started with the efforts to identify the Huntington’s disease gene in the 1980s,
Tanita Allen, a dedicated advocate for Huntington’s Disease and author of her much labored memoir “We Exist”, is starting a new column for the IHA website, called Be Empowered by
Hello, everyone! I am truly honored to introduce myself as the newest columnist for the International Huntington Association’s online platform. Writing for this community is not only a privilege, but
La conferința EHDN & Enroll-HD de anul trecut de la Strasbourg, am avut privilegiul de a o intervieva pe Siri Hagen Kjølaas, Ph.D., pentru a discuta despre cercetarea sa inovatoare privind provocările psihosociale cu care se confruntă
SOM Biotech prezintă rezultatele studiului de fază 2b cu SOM3355, demonstrând un profil unic cu îmbunătățiri robuste ale coreei la pacienții cu boala Huntington și un profil sigur fără somnolență,
Asociația Internațională Huntington, în colaborare cu Asociația Europeană Huntington, organizează o campanie pentru Ziua Bolilor Rare 2025, pe 28 februarie. Sloganul pentru RDD din acest an
Romanian 
English 
Arabic 
Bulgarian 
Chinese 
Czech 
Danish 
Dutch 
Estonian 
Finnish 
French 
German 
Greek 
Hungarian 
Indonesian 
Italian 
Japanese 
Latvian 
Lithuanian 
Polish 
Portuguese 
Russian 
Slovak 
Slovenian 
Spanish 
Swedish 
Turkish 
Ukrainian